
Detailed clinical trial results for cardiovascular disease drug candidates from Swiss multinational pharmaceutical company ‘Novartis’ and Danish pharmaceutical company ‘Novo Nordisk’ were presented on the 7th (local time) at the American Heart Association’s annual scientific sessions. REUTERS/Tom Little/Yonhap News, REUTERS/Charles Platiau/File Photo/Yonhap News
Detailed clinical trial results have been released for two new drug candidates that had been expected to lower the risk of developing cardiovascular disease. These drugs had already been deemed clinical failures when key results were announced in July and September. Some hope remained that they might benefit certain subsets of patients, but even the detailed analyses failed to show any advantage over placebo.
According to a report by the New York Times on the 7th (local time), the detailed clinical trial results of ‘pelacarsen’ from Swiss multinational pharmaceutical company ‘Novartis’ and ‘ziltivekimab’ from Danish pharmaceutical company ‘Novo Nordisk’ were presented that day at the American Heart Association’s annual scientific sessions. The findings were simultaneously published in the international medical journal the New England Journal of Medicine.
Cardiologists had been waiting for the detailed results for months after news broke that the two drugs had failed in clinical trials. They hoped the outcomes had fallen just short of the threshold for statistical significance, or that at least some patient subgroups might have shown a benefit.
Carol E. Watson, professor of medicine and cardiology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), said, “At the time, the entire cardiovascular research and clinical community was deeply shocked.”
However, the detailed results still revealed no evidence that the drugs helped patients. On none of the evaluated endpoints did they perform better than placebo. Watson said, “It would be hard for the conclusion of no difference to be any clearer.”
Novartis’ pelacarsen, a substance that lowers lipoprotein(a) (Lp(a)), had been highly anticipated as a next-generation therapy rivaling statins, the standard treatment widely used for cardiovascular disease prevention.
Lp(a) is a blood protein with a structure similar to low-density lipoprotein (LDL), often called “bad cholesterol.” There has been virtually no serious disagreement over the idea that Lp(a) is a legitimate target for cardiovascular disease prevention. Large-scale epidemiological follow-up studies have clearly shown that higher blood concentrations of Lp(a) are proportionally associated with an increased risk of cardiovascular disease.
Novo Nordisk’s ziltivekimab suppresses inflammation, which is known to play a key role in the process by which fat and other substances accumulate on arterial walls. Yet in these trials, neither drug was able to actually reduce the incidence of cardiovascular events.
Some observers have suggested that the underlying hypothesis for these treatments might itself be wrong. Just as gray hair is a sign of aging rather than its cause, inflammation might be a sign of disease rather than its root cause.
In September, Novo Nordisk announced it would halt two other ongoing clinical trials of ziltivekimab in patients with heart failure, concluding that the drug did not benefit patients.
Despite this, Paul Ridker, director of the Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital in the United States, who led the ZEUS trial of ziltivekimab, said he is not giving up. Ridker explained, “There is genetic, epidemiologic, and animal-experiment evidence supporting the idea that targeting other proteins within the same inflammatory pathway can help prevent heart attacks and strokes.”
He continued, “We already know that this approach can work,” adding, “The question is how to find the right drug for the right patients.”
Steven Nissen, chief academic officer of the Heart, Vascular & Thoracic Institute at the Cleveland Clinic in the United States, who led the HORIZON trial of pelacarsen, expressed concern that disappointed patients might drop out of two other clinical trials evaluating different Lp(a)-lowering drugs.
“A single clinical trial does not necessarily provide all the answers,” Nissen stressed, adding that elevated Lp(a) levels remain “a very powerful risk factor.” He also suggested that participants in the HORIZON trial may have had such advanced heart disease that it was too late for the drug to show an effect.
Roger Blumenthal, director of the Ciccarone Center for the Prevention of Cardiovascular Disease at Johns Hopkins University in the United States, offered another possible reason for the failed trials. He noted that other risk factors such as blood pressure and LDL cholesterol were already well controlled in participants, making it difficult to reduce risk further by lowering Lp(a) levels.
All participants in the HORIZON trial were taking medications that inhibit blood clot formation. These pre-existing therapies may have masked any additional benefits of pelacarsen.
Whatever the cause, the conclusion that pelacarsen failed to demonstrate efficacy in this clinical trial has not changed. “We saw no results that would justify saying the drug had an effect,” Nissen said.
Copyright ⓒ DongA Science. All rights reserved.